{"disease":{"id":"enterobacter-infection","name":"Enterobacter Infection","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"colistimethate-sodium","indication_name":"Enterobacter Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coly-Mycin M","generic_name":"COLISTIMETHATE SODIUM","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"colimycin","indication_name":"Enterobacter Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"colimycin","company_name":"Poitiers University Hospital","drug_phase":"phase_1","molecular_target":"Melanocortin receptor 3, Melanocortin receptor 5, Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"colistin","indication_name":"Enterobacter Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coly-Mycin S","generic_name":"COLISTIN","company_name":"Par Sterile Products","drug_phase":"marketed","molecular_target":"Melanocortin receptor 3","drug_class":"colistin","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxon","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ceftazidime","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"tazicef","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"norfloxacin","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ceftazidim","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":13,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07039955","title":"Effect of Daily Chlorhexidine Bathing and Antibiotic/PPI Stewardship on Prevention of CPE Transmission and Infection","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5760,"lead_sponsor_name":"Chuncheon Sacred Heart Hospital","has_results":false},{"nct_id":"NCT03924934","title":"Community-associated Highly-Resistant Enterobacterales","phase":"","overall_status":"COMPLETED","enrollment_count":2172,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":false},{"nct_id":"NCT05979545","title":"EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":1900,"lead_sponsor_name":"National University of Singapore","has_results":false},{"nct_id":"NCT03671967","title":"PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":1084,"lead_sponsor_name":"Rambam Health Care Campus","has_results":false},{"nct_id":"NCT05871476","title":"Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated Animals","phase":"NA","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Hanoi University of Public Health","has_results":false},{"nct_id":"NCT03401242","title":"Prevalence of ESBL and CPE in French Nursing Homes","phase":"","overall_status":"COMPLETED","enrollment_count":734,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04535661","title":"Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children","phase":"","overall_status":"RECRUITING","enrollment_count":536,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT04014413","title":"Safety and Efficacy of Fecal Microbiota Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT05850871","title":"Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies","phase":"NA","overall_status":"UNKNOWN","enrollment_count":427,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT06051513","title":"Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","phase":"NA","overall_status":"RECRUITING","enrollment_count":404,"lead_sponsor_name":"Southeast University, China","has_results":false},{"nct_id":"NCT04903886","title":"Intensive Care Unit Acquired Infections in Patients Colonized With Extended Spectrum Enterobacteriaceae","phase":"","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04167228","title":"Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria","phase":"","overall_status":"COMPLETED","enrollment_count":348,"lead_sponsor_name":"Maimónides Biomedical Research Institute of Córdoba","has_results":false},{"nct_id":"NCT07172932","title":"ANTIBIOTIC-RESISTANT ENTEROBACTERALES BLOODSTREAM INFECTIONS AND RISK FACTORS IN PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT","phase":"","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"Ankara City Hospital Bilkent","has_results":false},{"nct_id":"NCT05985057","title":"A Novel Approach to Antimicrobial Resistance: Machine Learning Predictions for Carbapenem-Resistant Klebsiella in ICUs","phase":"","overall_status":"COMPLETED","enrollment_count":289,"lead_sponsor_name":"Kocaeli University","has_results":false},{"nct_id":"NCT07200999","title":"Prevalence of Carriage of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteria in Preterm Premature Rupture of Membranes : A French Multicenter Cohort Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Centre Hospitalier de Saint-Denis","has_results":false},{"nct_id":"NCT06636890","title":"Correlation Analysis of Xpert Carba-R Detection of Non-colonized CRE in BALF and Rectal Swabs From Patients With LRTI","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT04699981","title":"Can the Relative Fecal Abundance of BLSE and the Digestive Microbiota be Predictive of the Risk of Infection in a Carrier Patient?","phase":"NA","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Fondation Hôpital Saint-Joseph","has_results":false},{"nct_id":"NCT04190316","title":"Factors Influencing the Fecal Relative Abundance of ESBL-producing Enterobacteriaceae in Intensive Care (BLSE-REA).","phase":"NA","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT03891433","title":"Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae","phase":"PHASE4","overall_status":"SUSPENDED","enrollment_count":198,"lead_sponsor_name":"Universidad del Norte","has_results":false},{"nct_id":"NCT04528043","title":"Infections and Colonization With the Third Group of Enterobacteriaceae in the Intensive Care Unit","phase":"","overall_status":"COMPLETED","enrollment_count":179,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03477084","title":"Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities","phase":"","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT03411590","title":"The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"FrieslandCampina WAMCO Nigeria PLC","has_results":false},{"nct_id":"NCT07086391","title":"Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.","phase":"","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Fujian Medical University Union Hospital","has_results":false},{"nct_id":"NCT05210387","title":"Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections","phase":"NA","overall_status":"TERMINATED","enrollment_count":107,"lead_sponsor_name":"Hospital Moinhos de Vento","has_results":false},{"nct_id":"NCT05516433","title":"Effect of Imipenem and Meropenem on the Digestive Microbiota and the Emergence and Carriage of Multidrug-resistant Bacteria","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Fondation Hôpital Saint-Joseph","has_results":false},{"nct_id":"NCT04583098","title":"The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Chuncheon Sacred Heart Hospital","has_results":false},{"nct_id":"NCT07160569","title":"Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05981430","title":"Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT04759001","title":"FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05258851","title":"Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"King Faisal Specialist Hospital & Research Center","has_results":false},{"nct_id":"NCT03338738","title":"Impact of Beta-lactams on the Microbiota and Relative Fecal Abundance of Mulltidrug Resistant Bacteria","phase":"NA","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Fondation Hôpital Saint-Joseph","has_results":false},{"nct_id":"NCT05611892","title":"Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients","phase":"","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04790565","title":"Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Rambam Health Care Campus","has_results":false},{"nct_id":"NCT05055479","title":"Nosocomial Outbreak of BHRe in an Intensive Care Unit During SARS-CoV-2 Pandemic","phase":"","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT04876430","title":"Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Hospital de Clinicas de Porto Alegre","has_results":false},{"nct_id":"NCT04276480","title":"Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.","phase":"NA","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT04146337","title":"Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Rambam Health Care Campus","has_results":false},{"nct_id":"NCT04760665","title":"Clinical Trial to Demonstrate the Effectiveness of Fecal Microbiota Transplantation for Selective Intestinal Decolonization of Patients Colonized by Carbapenemase-producing Klebsiella Pneumoniae","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Maimónides Biomedical Research Institute of Córdoba","has_results":false},{"nct_id":"NCT05355350","title":"PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Rambam Health Care Campus","has_results":false},{"nct_id":"NCT04785924","title":"Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false}],"total":40},"guidelines":[],"source":"Drug Landscape verified database"}